Bayer Faces Supreme Court on Big Roundup Lawsuit Fight
The U.S. Supreme Court will hear Bayer AG’s attempt to stop thousands of lawsuits that claim the company failed to warn consumers about Roundup’s alleged cancer risk. Bayer seeks federal pesticide rules that would block state‑law claims, such as the one that awarded a Missouri jury $1.25 million to John Durnell, who alleges glyphosate caused his lymphoma after prolonged exposure.
Key Arguments
| Bayer | Durnell’s Lawyers |
|---|---|
| The EPA has repeatedly stated glyphosate does not cause cancer. | Missouri law requires adequate warnings and is not preempted by FIFRA. |
| Glyphosate labels, approved by the EPA, lack a warning. | State law supersedes federal preemption in this case. |
If the Court sides with Bayer, many more cases could end.
Background
- Acquisition: Bayer bought Roundup in 2018 by acquiring Monsanto for $63 billion.
- Product Changes: Since the surge in lawsuits, Bayer removed glyphosate from its consumer products and warned farmers that legal battles could jeopardize supply.
- Settlement Offer: In February, the firm offered a $7.25 billion settlement to resolve most current and future claims, excluding appeals or other cases that could total about $1 billion.
Legal Focus
The core issue is the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which sets federal standards for pesticide labeling and bars states from adding extra requirements. Bayer argues Durnell’s claim is preempted by FIFRA because the EPA has approved labels that do not warn of cancer.
Stakeholder Positions
- Support for Bayer: Many farming groups and the Trump administration.
- Opposition to Bayer: Environmental, farm‑worker, and public health advocates.
A recent poll showed 63 % of people oppose protecting companies from lawsuits over cancer‑linked products, even if they warn consumers.
Timeline
The Supreme Court is expected to decide by the end of June. If Bayer wins, it could change how pesticide lawsuits are handled across the country.
